Infant formula counterfeits & terrorism
This article was originally published in The Tan Sheet
FDA recently "became aware of infant formula that was tampered with that was used to fund al Quaeda operatives," FDA Associate Commissioner for Regulatory Affairs Steven Niedelman said at the Food & Drug Law Institute's Enforcement & Litigation Conference in Washington D.C. Sept. 23. "Terrorism has become a big issue for the agency and one that all firms need to take into account," he noted. House Energy & Commerce Committee Senior Counsel Alan Slobodin asserted two years ago that terrorist organizations often are financed through counterfeit trade of consumer products such as infant formula (1"The Tan Sheet" Oct. 8, 2001, In Brief)...
You may also be interested in...
FDA should heighten its focus on product security to ensure counterfeiting does not take place, not only for consumer safety, but to cut off a source of income for terrorists, asserted House Energy & Commerce Committee Senior Counsel Alan Slobodin.
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.